Indexing
All Issues
Submission
Author Guidelines
Reviewers
Editorial Members
Publication Fee
Vol.1 , No. 4, Publication Date: Oct. 24, 2014, Page: 32-44
 is the common risk factor for about 99% of cervical cancer infection worldwide. HPV causes cervical cancer through the up-regulation of COX. COX-1 and COX-2 which is present in small amount in every cell. It plays a key role in regulation of cervical cancer neoplasia. Cell viability was determined using cell titre blue by doubling dilution from 1,000,000 to 31,250 cells per ml on HT3. Dose response for Acetylsalicylic Acid ASA and SA was carried out at different concentrations from 0-20mM concentrations and incubated at different time intervals 24, 48 and 72hrs incubation. A 10mM concentration of ASA and Salisalic Acid (SA) was used to determine the caspase activity using caspaseglo on the cell line for the period of 0-24hrs incubations. Western blot was carried out using active anti- caspase3 antibody for caspase3 proteins. The number of cells was found to increase as the absorbance increases, but the relationship breaks up above 600000 cells per ml. Effects of drugs on the viability of HT3 indicated that SA has more effect by inhibiting the viability of HT3 from 10-20mM concentrations at 48 and 72hrs incubations. SA shows more differential effect on caspase with more increase in caspase activity from 8-16hrs incubations. Western blot shows no expression of protein for caspase3, using β actin as a housekeeping gene. This study indicates that SA has more effect on HT3 cervical cancer cell line. This finding might be as a result of differences in the chemical properties of the drugs.&picture=http://www.aascit.org/aascit/decorators/img/journal/922.jpg)
| [1] | Ibrahim Mohammed, Histopathology Department, Faculty of Medical Laboratory Sciences, Usmanu Danfodiyo University, Sokoto State, Nigeria. |
| [2] | Ahmad Muhammad Tangaza, Histopathology Department, Faculty of Medical Laboratory Sciences, Usmanu Danfodiyo University, Sokoto State, Nigeria. |
| [3] | Rilwanu Isah Tsamiya, Histopathology Department, Faculty of Medical Laboratory Sciences, Usmanu Danfodiyo University, Sokoto State, Nigeria. |
Cervical cancer is one the commonest type of cancers affecting women worldwide with high mortality rate. Human Papilloma Virus (HPV) is the common risk factor for about 99% of cervical cancer infection worldwide. HPV causes cervical cancer through the up-regulation of COX. COX-1 and COX-2 which is present in small amount in every cell. It plays a key role in regulation of cervical cancer neoplasia. Cell viability was determined using cell titre blue by doubling dilution from 1,000,000 to 31,250 cells per ml on HT3. Dose response for Acetylsalicylic Acid ASA and SA was carried out at different concentrations from 0-20mM concentrations and incubated at different time intervals 24, 48 and 72hrs incubation. A 10mM concentration of ASA and Salisalic Acid (SA) was used to determine the caspase activity using caspaseglo on the cell line for the period of 0-24hrs incubations. Western blot was carried out using active anti- caspase3 antibody for caspase3 proteins. The number of cells was found to increase as the absorbance increases, but the relationship breaks up above 600000 cells per ml. Effects of drugs on the viability of HT3 indicated that SA has more effect by inhibiting the viability of HT3 from 10-20mM concentrations at 48 and 72hrs incubations. SA shows more differential effect on caspase with more increase in caspase activity from 8-16hrs incubations. Western blot shows no expression of protein for caspase3, using β actin as a housekeeping gene. This study indicates that SA has more effect on HT3 cervical cancer cell line. This finding might be as a result of differences in the chemical properties of the drugs.
Keywords
Human Papillomavirus, Cyclooxygenase, HT3 Cervical Cancer, Acetylsalicylic Acid, Salicylic Acid, Caspase, Apoptosis
Reference
| [01] | World Health Organization. IARC GLOBOCAN report. Geneva: WHO, 2008. |
| [02] | Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. GLOBOCAN 2008 v2.0, Cancer incidence and mortality worldwide: IARC CancerBase No. 10 [Internet]. Lyon, France: International Agency for Research on Cancer; 2010. Available from: http://globocan.iarc.fr [accessed 12/07/2012]. |
| [03] | Muñoz N. and Bosch F X The causal link between HPV and cervical cancer and its implications for prevention of cervical cancer. Bulletin of the Pan American Health Organization 1996;30: 362–377. |
| [04] | Montero JA, Larkin JA, Houston SH, Toney J, Haley J Examining the complex relationship of human papillomavirus to cervical dysplasia and carcinoma. Medscape Women’s Health 1997. http://www.medscape.com/ Medscape/women/ |
| [05] | Muñoz N, Bosch FX, de Sanjosé S, Herrero R, Castellsagué X, Shah KV et al.International Agency for Research on Cancer Multicentre Cervical Cancer Study Group. Epidemiological classification of human papillomavirus types associated with cervical cancer. New England Journal of Medicine2003; 6: 518-527. |
| [06] | Muñoz N, Bosch FX, Castellsagué X, Díaz M, de Sanjose S, Hammouda D et al. Against which human papillomavirus types shall we vaccinate and screen? The international perspective. International Journal of Cancer2004;2: 278-285. |
| [07] | Subbaramaiah K and Dannenberg AJ. Papillomavirus 16 E6 and E7 oncoproteins: evidence of cyclooxygenase-2 transcription is regulated by human corepressor/coactivator exchange. Cancer Research2007;8: 3975-3985. |
| [08] | WHO. The World Health Report 1998. Life in the 21st century. A Vision for All. WHO, Geneva 1998. |
| [09] | Sood AK. Cigarette smoking and cervical cancer: meta-analysis and critical review of recent studies. American Journal of Preventive Medicine1991;7: 208–213. |
| [10] | La Vecchia C, Tavani A, Franceschi S, Parazzini F. Oral contraceptives and cancer: a review of the evidence. Drug Safety1996;14: 260–272. |
| [11] | Valerie B, Carol H, Clifford K, Philip H, Sarah D and Gillian R. Mortality associated with oral contraceptive use: 25 year follow up of cohort of 46,000 women from Royal College of General Practitioners’ oral contraception study. British Medical Journal1999;318: 96–100. |
| [12] | Jha PK, Beral V, Peto J, Hack S, Hermon C, Deacon J et al. Antibodies to human papillomavirus and to other genital infectious agents and invasive cervical cancer risk. Lancet 1993;341: 1116–1118. |
| [13] | Markowska J, Fischer N, Filas V, Fischer Z, Breborowicz J, and Markowski M.The role of Chlamydia trachomatis infection in cervical cancer development. European Journal of Gynaecological Oncology 1999;20: 144–146. |
| [14] | Cancer Research Campaign. Lung Cancer and Smoking, Factsheet 11.4. Cancer Research Campaign, London 1996. |
| [15] | DeVet HW and Sturmans F. Risk factors for cervical dysplasia: Implications for prevention. Public Health 1994;108: 241–249. |
| [16] | Lovejoy NC. Precancerous and cancerous cervical lesions: the multicultural ‘male’ risk factor. Oncology Nursing Forum 1994;21: 497–504. |
| [17] | Dong Z, Huang C, Brown RE, Ma WY. Inhibition of activator protein 1 activity and neoplastic transformation by aspirin. Journal of Biological Chemistry 1997;15: 9962-70. |
| [18] | Kulkarni S, Rader JS, Zhang F, Liapis H, Koki AT, Masferrer JL et al.Subbaramaiah K and Dannenberg AJ. Cyclooxygenase 2 is overexpressed in cervical cancer. Clinical Cancer Research 2001;2: 429-34. |
| [19] | Dursun P, Yuce K, Usubutun A and Ayhan A. Cyclooxygenase-2 expression in cervical intraepithelial neoplasia III and squamous cell cervical carcinoma, and its correlation with clinicopathologic variables. International Journal of Gynaecological Cancer 2007;1: 164-173. |
| [20] | Simmons DL, Botting RM and Hla T. Cyclooxygenase isoenzymes: the biology of prostaglandin synthesis and inhibition. Pharmacological Reviews 2004;3: 387-437. |
| [21] | Grösch S, Maier TJ, Schiffmann S, Geisslinger G. Cyclooxygenase-2 (COX-2)-independent anti-carcinogenic effects of selective COX-2 inhibitors. Journal of the National Cancer Institute 2006;11: 736-747. |
| [22] | Ulrich CM, Bigler J and Potter JD. Non-steroidal anti-inflammatory drugs for cancer prevention: promise, perils and pharmacogenetics. Nature Reviews Cancer 2006;2: 130-140. |
| [23] | Tiano HF, Loftin CD, Akunda J, Lee CA, Spalding J, SessomsAet al. Deficiency of either cyclooxygenase (COX)-1 or COX-2 alters epidermal differentiation and reduces mouse skin tumourigenesis. Cancer Research 2002;12: 3395-401. |
| [24] | Ferrandina G, Legge F, Ranelletti FO, Zannoni GF, Maggiano N, Evangelisti A et al.Cyclooxygenase-2 expression in endometrial carcinoma: correlation with clinicopathologic parameters and clinical outcome. Cancer 2002;4: 801-807. |
| [25] | Kune GA, Kune S and Watson LF. Colorectal cancer risk, chronic illnesses, operations, and medications: case control results from the Melbourne Colorectal Cancer Study. Cancer Research 1988;48: 4399–4404. |
| [26] | Cuzick J, Otto F, Baron JA, Brown PH, Burn J, Greenwald P et al. Aspirin and non-steroidal anti-inflammatory drugs for cancer prevention: an international consensus statement. Lancet Oncology 2009;5: 501-507. |
| [27] | Manzano A and Perez-Segura P. Colorectal cancer chemoprevention: is this the future of colorectal cancer prevention? Scientific World Journal 2012;2012: 327341. |
| [28] | Thun MJ, Henley SJ, Patrono C. Nonsteroidal anti-inflammatory drugs as anticancer agents: mechanistic, pharmacologic and clinical issues. Journal of National Cancer Institute 2002;4: 252-266. |
| [29] | Dannenburg AJ and Dubois RN eds. COX-2: a new target for cancer prevention and treatment. Progress in Experimental Tumour Research; 37. Basel: Karger, 2003. |
| [30] | Alfonso LF, Srivenugopal KS, Bhag G. Does aspirin acetylate multiple cellular proteins? (Review). Molecular medicine reports 2009;4: 533-537. |
| [31] | Vane JR and Botting RM. The mechanism of action of aspirin. Thrombosis Research 2003;5-6: 255-258. |
| [32] | Alfonso LF, Srivenugopal KS, Arumugam TV, Abbruscato TJ, Weidanz JA, Bhat GJ. Aspirin inhibits comptothecin-induced p21CIP1 levels and potentiates apoptosis in human breast cancer cells. International Journal of Oncology 2009;3: 597-608. |
| [33] | Brown JR and DuBois RN. COX-2: a molecular target for colorectal cancer prevention. Journal of Clinical Oncology 2005;12: 2840-2855. |
| [34] | Ranganathan S, Joseph J and Mehta JL. Aspirin inhibits human coronary artery endothelial cell proliferation by upregulation of p53. Biochemical and Biophysical Research Communications 2003;1: 143-146. |
| [35] | Lee SK, Park MS and Nam MJ. Aspirin has anti-tumour effects via expression of calpain gene in cervical cancer cells. Journal of Oncology 2008;2008: 285374. |
| [36] | Im SR and Jang YJ. Aspirin enhances TRAIL-induced apoptosis via regulation of ERK1/2 activation in human cervical cancer cells. Biochemical and Biophysical Research Communications 2012;1: 65-70. |
| [37] | Lu M, Strohecker A, Chen F, Kwan T, Bosman J, Jordan VCet al. Aspirin sensitizes cancer cells to TRAIL-induced apoptosis by reducing surviving levels. Clinical Cancer Research 2008; 10: 3168-3176. |
| [38] | Tsujii M, Kawano S, Tsuji S, Sawaoka H, Hori M and DuBois RN. Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell 1998; 5: 705-716. |
| [39] | Borthwick GM, Johnson AS, Partington M, Burn J, Wilson R and Arthur HM. Therapeutic levels of aspirin and salicylate directly inhibit a model of angiogenesis through a COX-independed mechanism. Federation of American Societies for Experimental Biology 2006; 12: 2009-2016. |
| [40] | Sales KJ and Jabbour HN. Cyclooxygenase enzymes and prostaglandins in the pathology of the endometrium. Reproduction 2003; 5: 559-567. |
| [41] | Chan AT, Giovannucci EL, Schernhammer ES, Colditz GA, Hunter DJ, Willett WCet al.. A prospective study of aspirin use and the risk for colorectal adenoma. Annals of Internal Medicine 2004; 140: 157–166. |
| [42] | Qiao L, Hanif R, Sphicas E, Shiff SJ and Rigas B. Effect of aspirin on induction of apoptosis in HT-29 human colon adenocarcinoma cells. Biochemical Pharmacology 1998; 55: 53-64. |
| [43] | Piqué M, Barragán M, Dalmau M, Bellosillo B, Pons G, Gil J. Aspirin induces apoptosis through mitochondrial cytochrome c release. Federation of European Biochemical Societies 2000; 480: 193–196. |
| [44] | Schwenger P, Alpert D, Skolnik EY, and Vilček J. Activation of p38 mitogen-activated protein kinase by sodium salicylate lead to inhibition of tumour necrosis factor-induced IκBα phosphorylation and degradation. Molecular Cell Biology 1998; 18: 78–84. |
| [45] | He H, Xia HH, Wang JD, Gu Q, Lin MC, Zou B et al. Inhibition of human telomerase reverse transcriptase by non-steroidal anti-inflammatory drugs in colon carcinoma. Cancer2006; 106: 1243–1249. |
| [46] | Castaño E, Dalmau M, Barragán M, Pueyo G, Bartrons R, and Gil J. Aspirin induces cell death and caspase-dependent phosphatidylserine externalization in HT-29 human colon adenocarcinoma cells. British Journal of Cancer 1999;81: 294–299. |
| [47] | Power JJ, Dennis MS, Redlak MJ, and Miller TA. Aspirin-induced mucosal cell death in human gastric cells: evidence supporting an apoptotic mechanism. Digestive Diseases and Sciences 2004; 49: 1518–1525. |
| [48] | Gao J, Niwa K, Sun W, Takemura M, Lian Z, Onogi K et al. Non-steroidal anti-inflammatory drugs inhibit cellular proliferation and up-regulate cyclooxygenase-2 protein expression in endometrial cancer cells. Cancer Science 2004; 95: 901–907. |
| [49] | Redlak MJ, Power JJ and Miller TA. Role of mitochondria in aspirin-induced apoptosis in human gastric epithelial cells. American Journal of Physiology - Gastrointestinal and Liver Physiology 2005;289: G731–G738. |
| [50] | Stark LA and Dunlop MG. Nucleolar sequestration of RelA (p65) regulates NF-κB-driven transcription and apoptosis. Molecular Cell Biology 2005; 25: 5985–6004. |
| [51] | Uyemura SA, Santos AC, Mingatto FE,Jordani MC, and Curti C. Diclofenac sodium and mefenamic acid: potent inducers of the membrane permeability transition in renal cortex mitochondria. Archives of Biochemistry and Biophysics 1997; 342: 231–235. |
| [52] | Oh KW, Qian T, Brenner DA and Lemasters JJ. Salicylate enhances necrosis and apoptosis mediated by the mitochondrial permeability transition. Toxicological Sciences 2003; 73: 44–52. |
| [53] | Mitchell JA, Saunders M, Barnes PJ, Newton R and Belvisi MG. Sodium salicylate inhibits cyclo-oxygenase-2 activity independently of transcription factor (nuclear factor kappaB) activation: role arachidonic acid. Molecular Pharmacology 1997; 6: 907-912. |
| [54] | Franz B and O’Neil EA. The effect of sodium salicylate and aspirin on NF-kappa B. Science 1995; 5244: 2017-2019. |
| [55] | Kopp E and Gosh S. Inhibition of NF-kappa B by sodium salicylate and aspirin. Science 1994; 5174: 956-959. |
| [56] | Wu KK. Aspirin and salicylate: an old remedy with a new twist. Circulation 2000; 17: 2022-2023. |
| [57] | Xu XM, Sansores-Garcia L, Chen XM, Matijivic-Aleksic N, Du M, and Wu KK. Suppression of inducible cyclooxygenase 2 gene transcription by aspirin and sodium salicylate. Proceedings of the National Academy of Sciences USA 1999; 9: 5292-5297. |
| [58] | Kutuk O and Basaga H. Aspirin inhibit TNF-alpha and IL-1- induced NF kappa B activation and sensitizeHeLa cells to apoptosis. Cytokine 2004; 5: 229-237. |
| [59] | Rigas B and Shiff SJ. Is inhibition of cyclooxygenase required for the chemopreventive effect of NSAIDs in colon cancer? A model reconciling the current contradiction. Medical Hypotheses 2000; 2: 210-215. |
| [60] | Han S, Inoue H, Flowers LC and Sidell N. Control of COX-2 gene expression through peroxisome proliferator-activated receptor gamma in human cervical cancer cells. Clinical Cancer Research 2003; 12: 4627-4635. |
| [61] | Jiang X and Wang X. Cytochrome C-mediated apoptosis. Annual Review of Biochemistry 2004;73: 87-106. |
| [62] | Klampfer L, Cammenga J, Wisniewski HG and Nimer SD. Sodium salicylate activates caspases and induces apoptosis in myeloid leukemia cell lines. Blood 1999; 7: 2386-2394. |
| [63] | Dikshit P, Chatterjee M, Goswami A, Mishra A and Jana NR. Aspirin induces apoptosis through the inhibition of proteasome function. Journal of Biological Chemistry 2006; 39: 29228-29235. |
| [64] | Núñez L, Valero RA, Senovilla L, Sanz-Blasco S, García-Sancho J, and Villalobos C. Cell proliferation depends on mitochondrial Ca2+ uptake: inhibition by salicylate. Journal of Physiology 2006; 1: 57-73. |
| [65] | Hsieh CC, Hernández-Ledesma B and de Lumen BO. Lunasin, a novel seed peptide, sensitizes human breast cancer MDA-MB-231 cells to aspirin-arrested cell cycle and induced apoptosis. Chemico-Biological Interactions 2010;186: 127-134. |
| [66] | De Luna-Bertos E, Ramos-Torrecillas J, García-Martínez O, Díaz-Rodríguez L, and Ruiz C. Effect of aspirin on cell growth of human MG-63 osteosarcoma line. Scientific World Journal 2012;2012: 834246. |
| [67] | Dhillon PK, Kenfield SA, Stampfer MJ, Giovannucci LE, and Chan MJ. Aspirin use after a prostate cancer diagnosis and cancer survival in a prospective cohort. Cancer prevention research (Philadelphia, Pa.) 2012;5: 1223-1228. |
| [68] | Pazhang Y, Ahmadian S,Javadifar N and Shafiezadeh M. COX-2 and surviving reduction may play a role in berberine-induced apoptosis in human ductal breast epithelial tumour cell line. Tumour Biology 2012;33: 207-214. |
| [69] | Kodela R, Chattopadhyay M, Goswami S, Gan ZY, Rao PN, Nia KV et al. Positional isomers of aspirin are equally potent in inhibiting colon cancer cell growth: differences in mode of cyclooxygenase inhibition. Journal of Pharmacology and Experimental Therapeutics 2013;345: 85-94. |
| [70] | Yan F, He Q, Hu X, Li W, Wei K, Li L et al. Direct regulation of caspase 3 by the transcription factor AP 2α is involved in aspirin induced apoptosis in MDA MB 453 breast cancer cells. Molecular Medicine Reports 2013;7: 909-914. |
| [71] | Xiaoxin M, Yingnan J, Yanxia L, Shu L, Yuanqi H, Hongwei L. Experimental research on the depressant effect of aspirin on Ishikawa adenocarcinoma endometrium cell growth. International Journal of Gynaecological Cancer 2009;19: 1182-1185. |
| [72] | Ou YQ, Zhu Wb, Li Y, Qiu PX, Huang YJ, Xie J et al. Aspirin inhibits proliferation of gemcitabine-resistant human pancreatic cancer cells and augments gemcitabine-induced cytotoxicity. ActaPharmacologicaSinica 2010;31: 73-80. |
| [73] | Park IS, Jo JR, Hong H, Nam KY, Kim JB, Hwang SH et al.. Aspirin induces apoptosis in YD-8 human oral squamous carcinoma cells through activation of caspases, down-regulation of Mcl-1, and inactivation of ERK-1/2 and AKT. Toxicology in Vitro 2010;24: 713-720. |
| [74] | Singh A and Rathaur S. Combination of DEC plus aspirin induced mitochondrial mediated apoptosis in filarial parasite Setariacervi. Biochimie2010;92: 894-900. |
| [75] | Hosomi Y, Yokose T, Hirose Y, Nakajima R, Nagai K, Nishiwaki Yet al.. Increased cyclooxygenase 2 (COX-2) expressions occur frequently in precursor lesions of human adenocarcinoma of the lung. Lung Cancer 2000; 30: 73-81. |
| [76] | Wong BC, Zhu GH and Lam SK. Aspirin induced apoptosis in gastric cancer cells. Biomedicine & Pharmacotherapy 1999; 53: 315-318. |
| [77] | Kim KM, Song JJ, An JY, Kwon YT and Lee YJ. Pre-treatment of acetylsalicylic acid promotes tumour necrosis factor-related apoptosis-inducing ligand-induced apoptosis by down regulating BCL-2 gene expression. Journal of Biological Chemistry 2005;280: 41047-41056. |
| [78] | Langley RE, Burdett S, Tierney JF, Cafferty F, Parmar MK and Venning G. Aspirin and cancer: has aspirin been overlooked as an adjuvant therapy? British Journal of Cancer 2011; 8: 1107-1113. |
| [79] | Liew G1, Mitchell P, Wong TY, Rochtchina E and Wang JJ. The association of aspirin use with age-related macular degeneration. Journal of American Medical Association Internal Medicine 2013; 4: 258-264. |
| [80] | Brinton LA. Epidemiology of cervical cancer: overview. In: Munoz K.V., Bosch K.V., Meheus A., editors. The Epidemiology of Human Papilloma Virus and Cervical Cancer. Oxford University Press 1992, 23–33. |
| [81] | Su PF and Wu FY. Differential suppression of the tumorigenicity of HeLa and SiHa cells by adeno-associated virus. British Journal Cancer 1996;73: 1533–1537. |
| [82] | Aspirin. Available from:http://www.wiley.com/legacy/college/boyer /0471661791 /cutting_edge/aspirin/aspirin.htm. Access on 13/11/2013. |
| [83] | Salicylic acid. Available from www. Inchem.org. Retrieved 2008-10-13. Access on 16/11/2013. |
| [84] | El Kebir D and Filep JG. Modulation of Neutrophil Apoptosis and the Resolution of Inflammation through β2 Integrins. Frontiers in Immunology 2013;4: 60. |
| [85] | Chan AT, Ogino S and Fuchs CS. Aspirin and risk of colorectal cancer in relation to expression of COX-2. New England Journal of Medicine 2007;356: 2131–2142. |
| [86] | Flossmann E and Rothwell PM, on behalf of the British Doctors Aspirin Trial and the UK-TIA Aspirin Trial. Effect of aspirin on long-term risk of colorectal cancer: consistent evidence from randomised and observational studies. Lancet 2007;369: 1603–1613. |
| [87] | Cole BF, Logan RF, Halabi S, Benamouzig R, Sandler RS, Grainge MJ et al.. Aspirin for chemoprevention of colorectal adenomas: meta-analysis of the randomized trials. Journal of National Cancer Institute 2009;101: 256–266. |
| [88] | Rothwell PM, Wilson M, Elwin CE, Norrving B, Algra A, Warlow CPet al.. Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomized trials. Lancet 2010;376: 1741–1750. |
| [89] | Elwood PC, Gallagher AM, Duthie GG, Mur LA and Morgan G. Aspirin, salicylates, and cancer. Lancet 2009; 9671: 1301-1309. |
| [90] | Hawley SA, Fullerton MD, Ross FA, Schertzer JD, Chevtzoff C, Walker KJ et al. "The Ancient Drug Salicylate Directly Activates AMP-Activated Protein Kinase". Science 2012; 6083: 918–922. |
| [91] | Western blotting (Theory) 2013. Available from: http://amrita.vlab.co.in/?sub=3&brch=187&sim=1331&cnt=1. Accessed on 12/9/2013. |
| [92] | Anti-active caspase 3 antibody 2013. Available from: http://www.abcam.com/active-caspase-3-antibody-e83-77-ab32042.html. Accessed on 26/10/2013. |
